Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NLSPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -91.61% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 13828 | Beta -0.3 | 52 Weeks Range 0.01 - 0.08 | Updated Date 03/15/2025 |
52 Weeks Range 0.01 - 0.08 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -227.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 457622 |
Shares Outstanding - | Shares Floating 457622 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focused on developing innovative therapies for patients with rare and complex central nervous system disorders.
Core Business Areas
- CNS Disorders: Focuses on developing treatments for attention-deficit/hyperactivity disorder (ADHD), narcolepsy, and other central nervous system disorders.
Leadership and Structure
The leadership team consists of seasoned professionals with experience in pharmaceutical development and commercialization. The company has a streamlined organizational structure to facilitate efficient decision-making.
Top Products and Market Share
Key Offerings
- Quilience: Quilience is NLS Pharmaceutics' lead product candidate, an extended-release controlled substance indicated for the treatment of ADHD. While specific market share data is not publicly available, competitors in the ADHD market include Tris Pharma, Teva Pharmaceutical, and Janssen Pharmaceuticals.
- Mazindol ER: Mazindol ER is another product in development that seeks to address narcolepsy. Competitors include Jazz Pharmaceuticals and Avadel Pharmaceuticals.
Market Dynamics
Industry Overview
The CNS therapeutics market is a large and growing market, driven by increasing awareness of mental health conditions and the development of new treatments.
Positioning
NLS Pharmaceutics aims to differentiate itself by focusing on unmet needs in the CNS space and developing novel formulations of existing drugs.
Total Addressable Market (TAM)
The TAM for ADHD and narcolepsy treatments is estimated to be in the billions of dollars. NLS Pharmaceutics is positioning itself to capture a portion of this market through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Innovative pipeline
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Small market cap
- High regulatory hurdles
Opportunities
- Positive clinical trial results
- Strategic partnerships
- Expansion into new markets
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Failure to secure funding
Competitors and Market Share
Key Competitors
- JAZZ
- TEVA
- RDHL
Competitive Landscape
NLS Pharmaceutics faces competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its novel formulations and focus on unmet medical needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by clinical development milestones.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline products.
Recent Initiatives: Recent initiatives include advancing clinical trials for Quilience and Mazindol ER.
Summary
NLS Pharmaceutics is a biopharmaceutical company in the early stages of development. Its success hinges on the successful clinical trials and commercialization of its lead product candidates. The company's innovative pipeline and experienced management team are strengths, but it faces challenges related to funding and competition.
Similar Companies
- JAZZ
- TEVA
- RDHL
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.